GB2156824A - Surgical cements - Google Patents

Surgical cements Download PDF

Info

Publication number
GB2156824A
GB2156824A GB08507703A GB8507703A GB2156824A GB 2156824 A GB2156824 A GB 2156824A GB 08507703 A GB08507703 A GB 08507703A GB 8507703 A GB8507703 A GB 8507703A GB 2156824 A GB2156824 A GB 2156824A
Authority
GB
United Kingdom
Prior art keywords
acid
component
tricalcium phosphate
weight
surgical cement
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB08507703A
Other versions
GB8507703D0 (en
GB2156824B (en
Inventor
Tatsumi Shiotsu
Toshio Adachi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meishintoryo Co Ltd
Original Assignee
Meishintoryo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP59056676A external-priority patent/JPS60253454A/en
Priority claimed from JP59137000A external-priority patent/JPS6117409A/en
Priority claimed from JP59192364A external-priority patent/JPS6171059A/en
Application filed by Meishintoryo Co Ltd filed Critical Meishintoryo Co Ltd
Publication of GB8507703D0 publication Critical patent/GB8507703D0/en
Publication of GB2156824A publication Critical patent/GB2156824A/en
Application granted granted Critical
Publication of GB2156824B publication Critical patent/GB2156824B/en
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/0047Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A61L24/0073Composite materials, i.e. containing one material dispersed in a matrix of the same or different material with a macromolecular matrix
    • A61L24/0084Composite materials, i.e. containing one material dispersed in a matrix of the same or different material with a macromolecular matrix containing fillers of phosphorus-containing inorganic compounds, e.g. apatite
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08KUse of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K3/00Use of inorganic substances as compounding ingredients
    • C08K3/32Phosphorus-containing compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Materials Engineering (AREA)
  • Engineering & Computer Science (AREA)
  • Surgery (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Composite Materials (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Materials For Medical Uses (AREA)
  • Dental Preparations (AREA)

Abstract

A surgical cement comprises: a) self-hardening alpha -tricalcium phosphate powder or self-hardening amorphous tricalcium phosphate powder; b) a surgically acceptable water-soluble poly(carboxylic acid); and c) water. The setting rate of the cement may be controlled by addition of an organic acid, e.g. glycolic or citric acid.

Description

SPECIFICATION Surgical cements and method for preparation thereof The present invention relates to a surgical cement, more particularly the invention pertains to a surgical cement containing a-tricalcium phosphate and/or amorphous tricalcium phosphate as the principal component and a method for preparing the same.
To date, many materials applicable to the living body such as plastics materials or various kinds of metals, for example, gold, silver, alloys of palladium, Ni-Cr alloys, Co-Cr alloys, amalgam, stainless steel, titanium alloys have been proposed and they have been used in many fields such as orthopaedics and dentistry. These materials have many applications for tooth crowns, or the root of a tooth, and further they have been tried for use in artificial bones, artificial joints or the like.They have a high reliability in their mechanical strength and are capable of precision processing, but they have various undesirable characteristics such as dissolution, corrosion, deterioration due to the severe environmental conditions in the living body and they suffer from fatigue during the long-term service and accompany a foreign substance-forming reaction, (for instance the formation of secondary caries).
Then, ceramics materials having a relatively good affinity for living tissues have recently been paid great attention.
For example, artificial bones, artificial joints and the artificial root of a tooth composed of Awl203 as single crystal, or as a sintered body thereof, or those constituted by hydroxyapatite have been proposed.
However, these implant materials have the disadvantages that they are too hard and fragile, these being common to the ceramics. Many problems to be solved still remain in order to adopt them as the material for artificial bones and the root of a tooth.
A cement in which orthophosphoric acid solution is conventionally used as the setting solution, is known in the field of surgical cement. For instance, zinc phosphate cement is obtained by kneading zinc oxide with about 70% aqueous orthophosphoric acid solution and silicate cement is used in the form of a product of kneaded silicate glass with aqueous phoshoric acid solution. However, these cements are highly acidic due to the phosphoric acid used and accordingly, they cause pulpal injury effects and moreover they have insufficient adhesion with teeth.
U.S. Patent Nos. 3,655,605, 3,741,926, 3,751,391 and 3,804,794 propose zinc oxidepolycarboxylate cement in which aqueous poly(carboxylic acid) solution having a weak pulpal injury is used instead of the aqueous orthophosphoric acid solution.
In addition, ionomer cements have been developed in order to modify the compressive strength of cements and in said ionomer cements fluoroaluminosilicate is used in place of zinc oxide, which is set with an aqueous solution of poly(carboxylic acid) (see, for instance, U.S.
Patent Nos. 3,814,717, 4,016,124, 4,089,830 and British Patent No. 1,316,129). However, the ingredients used in these cements differ chemically from those of the teeth and bones and therefore, many problems to be overcome still remain, for example that these are less compatible with living tissues, that they irritate pulpal tissues and that they penetrate into the dentinal tubule and the like.
Moreover, in order to adjust the setting speed of carboxylate cements composed of zinc oxide and poly(carboxylic acid), there have been proposed, for example, a composition which is prepared from the carboxylate cement by adding, as a filler, a small amount of calcium phosphate powder thereto (see U.S. Patent Nos. 3,655,605, 3,751,391 and 4,288,355); and a cement composition obtained by mixing hydroxyapatite as principal component with an inorganic powder, such as ZnO, CaO, Al203, Ca3(PO4)2, SiO2 and poly(carboxylic acid) (see, for example, Japanese Patent Laid-Open Appln. No. 83605/1983).
However, such surgical cements do not satisfy the requirements for compatibility with living tissues and for compressive strength at the same time.
The materials applied to the living body are always in contact with the living tissues and are subjected to long-term service. Therefore, they must be safe, that is to say, they must not have harmful effects on the living body such as tumorigenesis and also they must not irritate the tissues around the part where the cement is filled or applied. In addition, they should have a good compatibility with the living cells, i.e., a good adhesion to them and a self-ossification, in other words, the assimilation between neonatal bones and the surface of the material.
Under these circumstances, there has been a strong need for the development of materials for living organisms which include components similar to principal components of the teeth or bones and which have an excellent compressive strength.
According to the present invention there is provided a surgical cement comprising: a) a component (A) composed of at least one member selected from the group consisting of self-hardening a-tricalcium phosphate powder and self-hardening amorphous tricalcium phosphate powder; b) a component (B) of surgically acceptable water-soluble poly(carboxylic acid); and c) water.
According to the present invention there is further provided a process for preparing a surgical cement which comprises preparing a mixture by admixing (a) a component (A) of at least one member selected from the group consisting of self-hardening a-tricalcium phosphate powder and self-hardening amorphous tricalcium phosphate and (b) a component (B) of a powdered surgically acceptable water-soluble poly(carboxylic acid), and adding a desired amount of water, or by adding an aqueous solution of component (B) to component (A); then kneading the mixture thus obtained to convert the mixture to a fluidized or plastic state.
By means of this invention surgical cements can be provided which are applicable in the fields of medicine and dentistry, which have components quite similar to those of the teeth or bones of the living organisms, so that they do not cause a foreign substance-formation reaction and they are quite excellent in their compatibility with the living organism.
By means of this invention it is possible to provide a surgical cement which can be filled into root canals of teeth or into defects and vacant parts formed due to diseases or external factors.
It is also possible by means of this invention to provide a surgical cement applicable as a restorative material to repair the alveolar bone eroded by degeneration and as a filler for tooth and bone fissures which are formed due to external factors such as, for example, periodontosis and traffic accidents.
By means of this invention it is also possible to provide a surgical cement of a high compressive strength, which is also applicable to the case where a high strength is required immediately after filling.
It is further possible by means of this invention to provide a surgical cement, by which the structure and functions of injured parts and vacant parts (cavities) are repairable or restorable.
In the term "self-hardening a-tricalcium phosphate and/or self-hardening amorphous tricalcium phosphate" used in the surgical cement of this invention, the term "self-hardening" means that these phosphates react with surgically acceptable water-soluble poly(carboxylic acid), disclosed below in more detail, to set together.
In order to attain the objects of this invention, self-hardening a-tricalcium phosphate [a- Cas(PO42] powder and/or self-hardening amorphous tricalcium phosphate (Ca3(P04)2,xH20] powder must be used.
In general, said a-tricalcium phosphate may be prepared according to one of the following methods. For example, one method comprises heating dried calcium hydrogen phosphate dihydrate [CaHPO4 2H2O], at a temperature of from about 300 to 500"C to form y-calcium pyrophosphate (y-Ca2P207), then uniformly mixing equimolar amounts of y-calcium pyrophosphate and calcium carbonate, calcining the mixture, after sufficiently drying, at a temperature of from 1,000 to 1,300 C, preferably around 1,200 C, for about one hour and finely pulverizing the calcined product to obtain powder having a particle size equal to or less than 100cm.
Another method for preparing a-tricalcium phosphate [a-Ca3(P04)2J powder comprises uniformly mixing calcium hydrogen phosphate dihydrate and calcium carbonate at a molar ratio of 2:1, then calcining the mixture under the same conditions as disclosed above and pulverizing the calcined product according to the aforementioned manner.
The a-tricalcium phosphate powder thus obtained may be further processed according to the following procedures which comprise compressing the a-tricalcium phosphate powder, calcining the pressed powder at a temperature of from 1,200 to 1,500 C, preferably 1,200 to 1,300 C for at least one hour and then pulverizing the calcined product as in the case mentioned above, to form fine powder having a particle size distribution of 0.5 to 20 pm.
In addition, a-tricalcium phosphate may be prepared by compressing amorphous tricalcium phosphate under pressure and calcining and pulverizing according to the same procedure as mentioned above.
In the latter method, in which the calcination and the pulveriztion treatments are carried out twice, the first treatment is effected to form -tricalcium phosphate and the second treatment is carried out to improve density of the powder and to enhance the compressive strength.
However, the product obtained by the first treatment may still be used in the surgical cement as the principal component thereof and provides satisfactory results.
Furthermore, if desired, there may be added to the cement 0.1 to 10% by weight, preferably 0.1 to 2% by weight of aluminium phosphate before the single calcination step or before the first or the second calcination and pulverization steps, in order to improve the compressive strength of the final surgical cement.
On the other hand, amorphous tricalcium phosphate may generally be obtained by a process which comprises reacting an aqueous solution of a calcium salt and an aqueous solution of phosphate, separating the product by filtration at a low temperature and drying it.
Calcium nitrate is the preferred calcium salt and ammonium phosphate is preferably used as the phosphate. The reaction is preferably carried out at a pH of from 10 to 1 2 and the reaction is similar to the known wet synthesis of calcium hydroxide apatite. After the completion of the reaction, the processes such as the separation by filtration, drying and pulverization are carried out at a low temperature. This is an important condition for maintaining the calcium phosphate thus formed in the amorphous state without causing any crystallization.
In this method, it is, therefore, preferable to carry out the separation by filtration, drying and pulverization at a temperature of from - 10"C to + 10"C. In particular, the upper limit is critical in the process as this is required to maintain the reaction product in the amorphour state as mentioned above.
The drying operation may be, for example, lyophilization (freeze-drying).
Another essential component of the cement of the present invention is a surgically-acceptable water-soluble poly(carboxylic acid). All the known poly(carboxylic acids conventionally used in surgical cement, such as cement containing zinc oxide as the principal component or ionomer cement dislosed in U.S. Patent No. 4,089,830, may be used in the present invention without any difficulties.
The preferred poly(carboxylic acids) are those prepared by the homo-polymerization or copolymerization of unsaturated aliphatic carboxylic acids and copolymerization of these acids with other unsaturated aliphatic monomers.
The poly(carboxylic acid) solution which is used in the preferred surgical cement according to the invention may be prepared by any of the customarily used polymerization techniques. For example, polymerization may be carried out in aqueous solution in the presence of ammonium persulphate and various chain transfer agents to give solutions containing up to about 30% of the polymer. This solution may then be concentrated, if necessary, to give a more viscous solution, or freeze-dried to give a solid particulate poly(carboxylic acid).
Various other acrylic monomers may be included in the polymerizing system to give carboxylic acid copolymers having modified properties, provided that the carboxylic acid copolymer is sufficiently soluble in water and reacts with a tricalcium phosphate powder in the required manner.
Particularly preferred poly(carboxylic acids) are (i) homopolymers of acrylic acid, or (ii) copolymers of (a) acrylic acid, preferably in an amount of 60 to 99.9% by weight, as the principal component and (b) preferably 0.1 to 40% by weight of at least one unsaturated monomer selected from the group consisting of itaconic acid, maleic acid, fumaric acid, methacrylic acid, aconitic acid, citraconic acid, glutaconic acid, mesaconic acid, tiglic acid and a lower alkylester thereof (the alkyl group having 1 to 5 carbon atoms), and a lower alkylester of acrylic acid (C1 to C5 alkyl).
The surgically acceptable water-soluble poly (carboxylic acid) useful in the surgical cement of the invention preferably has a viscosity-average molecular weight of from 2,000 to 200,000, more preferably from 5,000 to 150,000, when determined by the method of Sakamoto (Chem.
Abstr., 58, 13160C).
The poly(carboxylic acid) may be used in the form of powder or in the form of an aqueous solution having a concentration ranging from 10 to 60% by weight, preferably 25 to 55% by weight.
The preferred surgical cement according to the invention comprises (a) 23 to 75% by weight, most preferably 33 to 72% by weight of at least one member (component (A)) selected from the group consisting of self-hardening a-tricalcium phosphate and self-hardening amorphous tricalcium phosphate, (b) 2 to 46% by weight, most preferably 7 to 37% by weight of a poly(carboxylic acid) (component (B)) and (c) 10 to 69% by weight, most preferably 1 2 to 50% by weight of water.
When component (B) is used in the form of an aqueous solution having a concentration of 10 to 60% by weight, preferably 25 to 55% by weight, the ratio of component (A) to the aqueous solution of component (B) is from 0.3:1 to 3.0:1, preferably from 0.5:1 to 2.5:1.
Even if the poly(carboxylic acid) is used in aqueous solution, the respective components must be adjusted so that the amount thereof falls within the aforementioned range.
The surgical cement according to the invention is preferably adjusted so that the weight ratio of the surgically acceptable water-soluble poly(carboxylic acid) to the self-hardening a-tricalcium phosphate falls within the range of from 0.4 to 0.6 and that the weight ratio of water to the self-hardening a-tricalcium phosphate falls within the range of from 0.4 to 0.7, in particular when the surgical cement is used in applications in which high compressive strength is needed.
Furthermore, in the surgical cement of the invention, many other organic acids other than poly(carboxylic acid) may be included preferably in an amount up to 10% by weight, in order to control the setting speed during its application for repairing or restoring the tooth canals and so on.
In the case where the organic acid is used in the form of aqueous solution, the amount of water present in the aqueous solution of the organic acid is previously adjusted so that the total amount thereof falls within the range mentioned above.
As the organic acid which is preferably used in the surgical cement of the invention, there may be mentioned, for example, glycolic acid, glutamic acid, pantothenic acid, lactic acid, tartaric acid, citric acid, malic acid, all of which may be used singly or as a mixture containing two or more of them.
Surgical cements can be obtained according to the invention, by combining a-tricalcium phosphate and/or amorphous tricalcium phosphate with poly(carboxylic acid), the cement being suitable for use as a root canal filling material, a lining cement, or as a restorative agent for use in alveolar bones, and having good compatibility with living tissues.
The invention will now be described in detail with reference to the accompanying Examples, which are purely illustrative. In the Examples, the terms "parts" and ''%'' are expressed as "parts by weight" and "% by weight" respectively.
Reference Example 1: Preparation of a-tricalcíum phosphate.
Calcium hydrogen phosphate dihydrate (CaHPO4 2H2O) was calcined at 500 C for 2 hours to form y-calcium pyrophosphate (y-Ca2P2O7). The resulting pyrophosphate was further calcined at 1,2004C for 2 hours after uniformly mixing with an equimolar amount of CaCO3, and cooled rapidly. The product thus obtained was then pulverized and passed through a 300 mesh sieve to adjust the particle size distribution. According to X-ray diffraction" the product is found to be a-tricalcium phosphate. This product is, hereunder, referred to as "a-TCP".
Reference Example 2: Synthesis of amorphous tricalcium phosphate.
The reaction of 31 of 0.5 mol/l aqueous solution of calcium nitrate (Ca(N03)2] with 21 of 0.5 mol/l aqueous solution of ammonium hydrogen phosphate [(NH4)2HPO4] was carried out by mixing them under a nitrogen gas stream at a temperature equal to or less than 5 C, while adjusting the pH to 11 by the addition of aqueous ammonia to the solution.
The resulting precipitates were filtered off below 0 C and washed with aqueous ammonia and then lyophilized for 24 hours. The product thus obtained was pulverized to form powder having the particle size of less than 300 mesh. The X-ray diffraction pattern thereof simply shows a halo and no peak attributed to a crystal is observed. This product is hereunder referred to as "A TCP".
Example 1 a-TCP and A-TCP synthesized in reference Examples 1 and 2 were kneaded with an aqueous poly(carboxylic acid) solution and, after 24 hours, the product was subjected to compressive strength measurement according to the method of JIS T-6602. The results obtained are shown in Table I. Copolymers of acrylic acid/itaconic acid (containing 15% of itaconic acid moiety, MW = 80,000 and 31,000) were used as the poly(carboxylic acid) in the example.
Table I.
Aqueous poly(carboxylic acid)soln. **Compressive strength Powder Mw* conen-(%) P/L (kg/cm &alpha;-TCP 80,000 25 1.3 180 &alpha;-TcP 80,000 30 1.3 320 i-TCP 80,000 45 1.3 720 i-TCP 80,000 50 1.3 770 < -TCP 80,000 45 0.5 150 i-TUe 80,000 45 1.0 630 d-TCP 80,000 45 1.8 800 i-TCP 31.000 45 1.3 700 A-TCP 80,000 45 1.3 600 *viscosity- average molecular weight (hereunder, all of the molecular weight (MW) is expressed as viscosity-average molecular weight).
**the weight ratio of the powder to the solution.
As evident from the results listed in Table I, a-TCP and A-TCP show sufficient compressive strength to use as a root canal filling agent and surgical cement.
Example 2 The a-TCP obtained in reference Example 1 was mixed with polyacrylic acid powder and the mixture was kneaded in the presence of a desired amount of water.
Then the measurement of compressive strength on the resulting product was carried out according to the same procedure as in Example 1. The results obtained are shown in Table II. In this Example, the copolymer of acrylic acid/itaconic acid (containing 15% itaconic acid moiety; MW: 80,000) was used as the poly(carboxylic acid).
Table II.
Amount of Amount of Amount of Compressive a- TCP poly(carboxylic acid) water strength (g) (g) (g) (kg/cm2) 2 0.7 1.2 530 2 1.0 1.2 580 2 1.1 1.2 550 Example 3 The procedures of Example 1 were repeated, except that various poly(carboxylic acids) were used. The results of the compressive strength measurements are listed in Table III.
Table III.
poly(carboxylic acid) Composition Mw concn. P/L Compressive (%) strength (kg/cm2) Polyacrylic acid 5,000 40 1.0 120 Polyacrylic acid 30,000 40 1.0 350.
acrylic acid/5% itaconic acid 66,000 40 1.3 680 copolymer acrylic acid/30% itaconic acid 30,000 40 1.3 690 copolymer acrylic acid/5% maleic acid 15,000 40 1.3 670 copolymer acrylic acid/10% fumaric acid 10,000 40 1.3 670 copolymer Example 4.
The setting solution obtained by adding 50% aqueous solution of an organic acid to an aqueous poly(carboxylic acid) solution was kneaded with a-TCP synthesized in reference Example 1. The compressive strength was measured on the resulting product in accordance with the procedure of Example 1. The results obtained are listed in Table IV. The aqueous poly(carboxylic acid) solution used was a 45% aqueous solution of acrylic acid/itaconic acid copolymer (containing 15% itaconic acid moiety; MW: 80,000).
Table IV.
Organic Acid Amount of the P/L Compressive Used. Organic acid soln. Strength (%) (kg/cm2) glycolic acid 5 1.0 650 glycolic acid 10 1.0 670 glycolic acid 20 1.0 580 citric acid 5 1.0 680 The addition of organic acid makes it possible to reduce the setting time.
Example 5.
The powder of a-TCP obtained in reference Example 1 was pressed under a pressure of 500kg/cm2 and 1,200kg/cm2, in a mould to form a tablet and then the tablet was calcined at 1 ,200"C for 2 hours. The calcined tablet was finely pulverized and the powder was passed through the 300 mesh sieve. Using the powder thus produced, the procedures of Example 1 were repeated and the compressive strength of the product was determined and the results are shown in the following Table V. The aqueous poly(carboxylic acid) solutions used herein were identical to those used in Example 4.
Table V.
Pressue Applied P/L Compressive Strength (kg/cm2) (kg/cm2) 500 1.5 990 500 2.0 1,130 1,200 1.5 960 Comparative Example 1.
ss-tricalcium phosphate (hereunder referred to as p-TCP) was prepared by calcining a mixture of calcium pyrophosphate and calcium carbonate by a conventional method, and hydroxyapatite (hereunder referred to as HAP) was also prepared by reacting calcium hydroxide with an aqueous phosphoric acid solution according to a conventional method. Each was kneaded with aqueous poly(carboxylic acid) solution (the same solution as that used in Example 4) and the compressive strength was measured on the resulting products as in Example 1. The results thus obtained are shown in Table VI.
Table VI.
Powder P/L Compressive Strength (kg /cm2) ss-TCP 1.3 no hardening HAP 1.3 30 As seen from the results listed in Table VI, ss-TCP has no self-hardening property and HAP has a quite low compressive strength. Although the latter can be set, it cannot be put into practical use, because of its low strength.
Comparative Example 2 To a mixture of a-TCP (obtained in reference Example 1) and water, there was added a small amount of an inorganic acid or an organic acid and kneaded. The resulting product was subjected to the measurement of the compressive strength according to the procedure of Example 1. Table VII shows the results obtained.
Table VII.
a-TC P Water Acid Used Amount Compressive (9) (g) thereof(ml) Strength (kg/cm2) 3 3.5 4N HNO3 0.2 46 3 3.5 4N HCI 0.2 47 3 3.5 5% CH3COOH 0.5 42 3 3.5 5% HCOOH 0.5 26 The results of Table VII show that all the cements thus obtained have low compressive strength of less than 50kg/cm2 and, as a result, these cements cannot be put into practical use.

Claims (14)

1. A surgical cement comprising: a) a component (A) composed of at least one member selected from the group consisting of self-hardening a-tricalcium phosphate powder and self-hardening amorphous tricalcium phosphate powder; b) a component (B) of surgically acceptable water-soluble poly(carboxylic acid); and c) water.
2. A surgical cement according to claim 1, which comprises; a) from 23 to 75% by weight of the component (A); b) from 2 to 46% by weight of the component (B); and c) from 10 to 69% by weight of water.
3. A surgical cement according to claim 1 or 2, in which the component (B) is in the form of an aqueous solution containing from 10 to 60% by weight of the component (B).
4. A surgical cement according to claim 3, which comprises; a) component (A) and b) an aqueous solution containing from 10 to 60% by weight of the component (B), the weight ratio of a) to b) being in the range of from 0.3:1 to 3.0:1.
5. A surgical cement according to any of the preceding claims, in which the self-hardening a-tricalcium phosphate powder is the powder obtained by compressing a-tricalcium phosphate under pressure, calcining it at a temperature of from 1,200 to 1,500do for at least one hour and then pulverizing it into fine powder.
6. A surgical cement according to any of claims 1 to 4, in which the self-hardening atricalcium phosphate powder is the powder obtained by compressing amorphour tricalcium phosphate under pressure, calcining the pressed tricalcium phosphate at a temperature of from 1,200 to 1,500to for at least one hour and then pulverizing it into fine powder.
7. A surgical cement according to any of the preceding claims, in which the poly(carboxylic acid) is a homopolymer of acrylic acid or a copolymer of (a) acrylic acid as principal monomer with (b) at least one unsaturated monomer selected from the group consisting of itaconic acid, maleic acid, fumaric acid, methacrylic acid, aconitic acid, citraconic acid, mesaconic acid, tiglic acid, and lower alkylesters thereof and lower alkylesters of acrylic acid.
8. A surgical cement according to any of the preceding claims, in which the poly(carboxylic acid) is a homopolymer of acrylic acid or a copolymer of (a) from 60 to 99.9% by weight of acrylic acid with (b) from 0.1 to 40% by weight of at least one unsaturated monomer selected from the group consisting of itaconic acid, maleic acid, fumaric acid, methacrylic acid, aconitic acid, citraconic acid, glutaconic acid, mesaconic acid, tiglic acid and lower alkylesters thereof and lower alkylesters of acrylic acid.
9. A surgical cement according to any of the preceding claims, in which the viscosityaverage molecular weight of the poly(carboxylic acid) is in the range of from 2,000 to 200,000.
10. A surgical cement according to any of the preceding claims, which further comprises at least one other organic acid in an amount up to 10% by weight.
11. A surgical cement according to claim 10, in which said other organic acid is at least one member selected from the group consisting of glycolic acid, lactic acid, glutamic acid, pantothenic acid, tartaric acid, citric acid, malic acid.
1 2. A process for preparing a surgical cement which comprises preparing a mixture by admixing (a) a component (A) of at least one member selected from the group consisting of selfhardening a-tricalcium phosphate powder and self-hardening amorphous tricalcium phosphate and (b) a component (B) of a powdered surgically acceptable water-soluble poly(carboxylic acid), and adding a desired amount of water, or by adding an aqueous solution of component (B) to component (A); then kneading the mixture thus obtained to convert the mixture to a fluidized or plastic state.
1 3. A process according to claim 12, in which the amount of component (A) is in the range of from 23 to 75% by weight, that of the component (B) is in the range of from 2 to 46% by weight and the water is used in an amount ranging from 10 to 69% by weight.
14. A process according to claim 12, in which the weight ratio of component (A) to the aqueous solution of component (B) is-in the range of from 0.3:1 to 3.0:1.
1 5. A process according to any of claims 1 2 to 14, in which the self-hardening a-tricalcium phosphate powder has been obtained by compressing a-tricalcium phosphate powder under pressure, calcining the compressed a-tricalcium phosphate at a temperature of from 1,200 to 1,500do for at least one hour and finely pulverizing the calcined product.
1 6. A process according to any of claims 1 2 to 14, in which the self hardening a-tricalcium phosphate is the powder obtained by compressing amorphous tricalcium phosphate powder under pressure, calcining the pressed tricalcium phosphate at a temperature of from 1,200 to 1,500 C for at least one hour and then finely pulverizing the calcined product.
1 7. A surgical cement substantially as herein described with reference to the Examples.
1 8. A process for preparing a surgical cement substantially as herein described with reference to and as illustrated in any of the Examples.
GB08507703A 1984-03-24 1985-03-25 Surgical cements Expired GB2156824B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP59056676A JPS60253454A (en) 1984-03-24 1984-03-24 Bone lack part and gap part filler composition
JP59137000A JPS6117409A (en) 1984-07-02 1984-07-02 Preparation of amorphous calcium phosphate and bio-compatible composition composed mainly thereof
JP59192364A JPS6171059A (en) 1984-09-13 1984-09-13 Composition for filling bone and tooth and its production

Publications (3)

Publication Number Publication Date
GB8507703D0 GB8507703D0 (en) 1985-05-01
GB2156824A true GB2156824A (en) 1985-10-16
GB2156824B GB2156824B (en) 1987-07-01

Family

ID=27295993

Family Applications (1)

Application Number Title Priority Date Filing Date
GB08507703A Expired GB2156824B (en) 1984-03-24 1985-03-25 Surgical cements

Country Status (3)

Country Link
AU (1) AU562042B2 (en)
DE (1) DE3510234A1 (en)
GB (1) GB2156824B (en)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837279A (en) * 1988-02-22 1989-06-06 Pfizer Hospital Products Corp, Inc. Bone cement
US4843112A (en) * 1987-03-12 1989-06-27 The Beth Israel Hospital Association Bioerodable implant composition
DE3806448A1 (en) * 1988-02-29 1989-09-07 Espe Stiftung COMPATIBLE MATERIAL AND MATERIALS AVAILABLE THEREFROM
US4900546A (en) * 1987-07-30 1990-02-13 Pfizer Hospital Products Group, Inc. Bone cement for sustained release of substances
DE3907663A1 (en) * 1989-03-09 1990-09-13 Espe Stiftung BONE REPLACEMENT FROM GLASIONOMIC CEMENT
US5085861A (en) * 1987-03-12 1992-02-04 The Beth Israel Hospital Association Bioerodable implant composition comprising crosslinked biodegradable polyesters
FR2670114A1 (en) * 1990-12-10 1992-06-12 Science Medecine Biocompatible and partially biodegradable material, such as a cement for embedding a prosthesis, in particular an orthopaedic prosthesis
FR2670115A1 (en) * 1990-12-10 1992-06-12 Science Medecine Biocompatible and biodegradable material, such as a cement for embedding a prosthesis, in particular an orthopaedic prosthesis
EP0639382A1 (en) * 1993-08-18 1995-02-22 Mit Pharmaca Ab Cement for medical use, method for producing the cement, and use of the cement
US6075067A (en) * 1994-08-15 2000-06-13 Corpipharm Gmbh & Co Cement for medical use, method for producing the cement, and use of the cement
EP1335887A1 (en) * 2000-10-16 2003-08-20 University Of South Carolina Biocompatible cement containing reactive calcium phosphate nanoparticles and methods for making and using such cement
US8809418B2 (en) 2004-03-21 2014-08-19 DePuy Synthes Products, LLC Methods, materials and apparatus for treating bone and other tissue
US8956368B2 (en) 2003-06-17 2015-02-17 DePuy Synthes Products, LLC Methods, materials and apparatus for treating bone and other tissue
US8992541B2 (en) 2003-03-14 2015-03-31 DePuy Synthes Products, LLC Hydraulic device for the injection of bone cement in percutaneous vertebroplasty
US9259696B2 (en) 2005-11-22 2016-02-16 DePuy Synthes Products, Inc. Mixing apparatus having central and planetary mixing elements
US9642932B2 (en) 2006-09-14 2017-05-09 DePuy Synthes Products, Inc. Bone cement and methods of use thereof
US9839460B2 (en) 2003-03-31 2017-12-12 DePuy Synthes Products, Inc. Remotely-activated vertebroplasty injection device
US9918767B2 (en) 2005-08-01 2018-03-20 DePuy Synthes Products, Inc. Temperature control system
US10494158B2 (en) 2006-10-19 2019-12-03 DePuy Synthes Products, Inc. Fluid delivery system

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2197329B (en) * 1986-09-10 1990-01-10 Showa Denko Kk Hard tissue substitute composition
DE3930921A1 (en) * 1989-01-20 1990-07-26 Schumann Klaus Operation needle for middle ear and accident surgery - with dependent drop of aq. mixt. of glass-ionomer material
DE8907335U1 (en) * 1989-06-15 1990-10-18 Espe Stiftung & Co Produktions- und Vertriebs KG, 8031 Seefeld Mixing device for pastes
DE4103876C2 (en) * 1990-02-09 1994-07-07 Asahi Optical Co Ltd A method of fixing a granular bone prosthesis and a kit for producing a granular bone prosthesis composition for use in the fixing method
DE4019617A1 (en) * 1990-06-20 1992-01-02 Thera Ges Fuer Patente IMPLANTABLE ACTIVE SUBSTITUTE MATERIAL
DE4023744A1 (en) * 1990-07-26 1992-02-06 Thera Ges Fuer Patente USE OF GLASIONOMIC ELEMENT FOR CONTROLLED TISSUE REGENERATIONS
DE4433811A1 (en) * 1994-09-22 1996-03-28 Voco Gmbh Stable, easily transported medical and dental cement mixt.
US9381024B2 (en) 2005-07-31 2016-07-05 DePuy Synthes Products, Inc. Marked tools

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4288355A (en) * 1978-05-22 1981-09-08 Minnesota Mining And Manufacturing Company Surgical cement composition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4288355A (en) * 1978-05-22 1981-09-08 Minnesota Mining And Manufacturing Company Surgical cement composition

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4843112A (en) * 1987-03-12 1989-06-27 The Beth Israel Hospital Association Bioerodable implant composition
US5085861A (en) * 1987-03-12 1992-02-04 The Beth Israel Hospital Association Bioerodable implant composition comprising crosslinked biodegradable polyesters
US4900546A (en) * 1987-07-30 1990-02-13 Pfizer Hospital Products Group, Inc. Bone cement for sustained release of substances
US4837279A (en) * 1988-02-22 1989-06-06 Pfizer Hospital Products Corp, Inc. Bone cement
DE3806448A1 (en) * 1988-02-29 1989-09-07 Espe Stiftung COMPATIBLE MATERIAL AND MATERIALS AVAILABLE THEREFROM
DE3907663A1 (en) * 1989-03-09 1990-09-13 Espe Stiftung BONE REPLACEMENT FROM GLASIONOMIC CEMENT
FR2670114A1 (en) * 1990-12-10 1992-06-12 Science Medecine Biocompatible and partially biodegradable material, such as a cement for embedding a prosthesis, in particular an orthopaedic prosthesis
FR2670115A1 (en) * 1990-12-10 1992-06-12 Science Medecine Biocompatible and biodegradable material, such as a cement for embedding a prosthesis, in particular an orthopaedic prosthesis
EP0639382A1 (en) * 1993-08-18 1995-02-22 Mit Pharmaca Ab Cement for medical use, method for producing the cement, and use of the cement
US6075067A (en) * 1994-08-15 2000-06-13 Corpipharm Gmbh & Co Cement for medical use, method for producing the cement, and use of the cement
US7527687B2 (en) 2000-10-16 2009-05-05 University Of South Carolina Biocompatible cement containing reactive calcium phosphate nanoparticles and methods for making and using such cement
US7081161B2 (en) 2000-10-16 2006-07-25 University Of South Carolina Biocompatible cement containing reactive calcium phosphate nanoparticles and methods for making and using cement
AU2002213313B2 (en) * 2000-10-16 2006-08-17 University Of South Carolina Biocompatible cement containing reactive calcium phosphate nanoparticles and methods for making and using such cement
EP1335887A1 (en) * 2000-10-16 2003-08-20 University Of South Carolina Biocompatible cement containing reactive calcium phosphate nanoparticles and methods for making and using such cement
EP1335887A4 (en) * 2000-10-16 2004-06-23 Univ South Carolina Biocompatible cement containing reactive calcium phosphate nanoparticles and methods for making and using such cement
US8992541B2 (en) 2003-03-14 2015-03-31 DePuy Synthes Products, LLC Hydraulic device for the injection of bone cement in percutaneous vertebroplasty
US9186194B2 (en) 2003-03-14 2015-11-17 DePuy Synthes Products, Inc. Hydraulic device for the injection of bone cement in percutaneous vertebroplasty
US10799278B2 (en) 2003-03-14 2020-10-13 DePuy Synthes Products, Inc. Hydraulic device for the injection of bone cement in percutaneous vertebroplasty
US9839460B2 (en) 2003-03-31 2017-12-12 DePuy Synthes Products, Inc. Remotely-activated vertebroplasty injection device
US10485597B2 (en) 2003-03-31 2019-11-26 DePuy Synthes Products, Inc. Remotely-activated vertebroplasty injection device
US8956368B2 (en) 2003-06-17 2015-02-17 DePuy Synthes Products, LLC Methods, materials and apparatus for treating bone and other tissue
US9504508B2 (en) 2003-06-17 2016-11-29 DePuy Synthes Products, Inc. Methods, materials and apparatus for treating bone and other tissue
US10039585B2 (en) 2003-06-17 2018-08-07 DePuy Synthes Products, Inc. Methods, materials and apparatus for treating bone and other tissue
US8809418B2 (en) 2004-03-21 2014-08-19 DePuy Synthes Products, LLC Methods, materials and apparatus for treating bone and other tissue
US9750840B2 (en) 2004-03-21 2017-09-05 DePuy Synthes Products, Inc. Methods, materials and apparatus for treating bone and other tissue
US9918767B2 (en) 2005-08-01 2018-03-20 DePuy Synthes Products, Inc. Temperature control system
US9259696B2 (en) 2005-11-22 2016-02-16 DePuy Synthes Products, Inc. Mixing apparatus having central and planetary mixing elements
US10631906B2 (en) 2005-11-22 2020-04-28 DePuy Synthes Products, Inc. Apparatus for transferring a viscous material
US9642932B2 (en) 2006-09-14 2017-05-09 DePuy Synthes Products, Inc. Bone cement and methods of use thereof
US10272174B2 (en) 2006-09-14 2019-04-30 DePuy Synthes Products, Inc. Bone cement and methods of use thereof
US10494158B2 (en) 2006-10-19 2019-12-03 DePuy Synthes Products, Inc. Fluid delivery system

Also Published As

Publication number Publication date
GB8507703D0 (en) 1985-05-01
AU562042B2 (en) 1987-05-28
DE3510234A1 (en) 1985-10-10
GB2156824B (en) 1987-07-01
AU4014785A (en) 1985-09-26

Similar Documents

Publication Publication Date Title
US4684673A (en) Surgical cement from amorphous tricalcium phosphate, poly(carboxylic acid) and water
GB2156824A (en) Surgical cements
US4677140A (en) Surgical cement containing α-tricalcium phosphate, poly(carboxylic acid) and water
EP0520690B1 (en) Calcium phosphate type hardening material for repairing living hard tissue
CA2157890C (en) Calcium phosphate hydroxyapatite precursor and methods for making and using the same
US4902649A (en) Hard tissue substitute composition
EP0729365B1 (en) Resorbable bioactive phosphate containing cements
US4668295A (en) Surgical cements
CA2438742C (en) A new calcium phosphate cement composition and a method for the preparation thereof
JPH02307845A (en) Hardening material
EP0538914B1 (en) Hardening material for medical and dental use
JPH03174311A (en) Storage-stable compound for on-site prepared calcium phosphate ore
JP2501213B2 (en) Bone glue
Greish et al. Formation and properties of hydroxyapatite–calcium poly (vinyl phosphonate) composites
WO2021189435A1 (en) Novel calcium phosphate composite active material having core-shell structure and preparation method therefor
JP2563186B2 (en) Method for producing calcium phosphate-based cured product
JPH01301543A (en) Curable composition
JP2548745B2 (en) Bone cement composition
JPS61270249A (en) Tetracalcium phosphate settable composition
JPH0526503B2 (en)
JP3558680B2 (en) Method for producing tetracalcium phosphate, tetracalcium phosphate obtained by this method, and cement composition containing this tetracalcium phosphate
JPH0331470B2 (en)
JPH07114804B2 (en) Medical curable composition
JPH01166762A (en) Medical and dental curable material
JPS61161206A (en) Dental cement composition

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20020325